股票代码：300015 股票简称：爱尔眼科 公告编号：2025-050 爱尔眼科医院集团股份有限公司 本次使用节余募集资金永久补充流动资金事项不存在损害公司股东利益的 情形，符合上市公司募集资金使用的相关法律法规，该事项决策和审议程序合法、 合规。 我们一致同意公司将上述项目的节余募集资金永久补充流动资金。 此项议案以 3 票赞成、0 票反对、0 票弃权获得通过。 特此公告。 2025 年 7 月 16 日 爱尔眼科医院集团股份有限公司监事会 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届监事会第二十 五次会议于 2025 年 7 月 16 日以通讯表决方式召开，会议通知于 2025 年 7 月 11 日以邮件方式送达，会议由监事会主席宁俊萍女士召集主持，应到监事 3 人，实 到监事 3 人，会议的召开符合《公司法》和《公司章程》的有关规定，会议合 法、有效。经审议，本次会议一致通过如下议案： 《关于部分募投项目结项并将节余募集资金永久补充流动资金的议案》 鉴于公司 2021 年度向特定对象发行股票募投项目中" ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-049 爱尔眼科医院集团股份有限公司 一、《关于部分募投项目结项并将节余募集资金永久补充流动资金的议案》 鉴于公司 2021 年度向特定对象发行股票募投项目中"贵州爱尔新建项目" 已达到预定可使用状态，除预留募集资金 2,053.96 万元用于支付部分合同尾款及 质保金外，公司拟将项目节余募集资金 11,967.54 万元（含利息收入）全部转入 自有账户用于永久补充流动资金，并于募投项目结算完毕后注销相关募集资金专 项账户。公司董事会授权公司财务部门办理本次专户注销事项，相关的募集资金 三方监管协议亦予以终止。 此项议案以 7 票同意、0 票反对、0 票弃权获得通过。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上刊登的《关于部分 募投项目结项并将节余募集资金永久补充流动资金的公告》。 第六届董事会第三十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届董事会第三十八 次会议于 2025 年 7 月 16 ...

Group 1: Company Development Strategy - The company focuses on deepening existing markets and expanding new ones through the "1+8+N" model, enhancing core hospitals' leading roles to integrate regional medical resources [1] - Organizational changes are initiated to boost efficiency and talent development, aiming for high-quality growth in the next decade [1] - Emphasis on patient-centered care by optimizing processes to improve patient experience and satisfaction [1] Group 2: Expansion of Services - The company aims to establish a "star-and-moon" structure in regional markets, integrating hospitals and outpatient departments for better service delivery [2] - New services are developed to address changing eye health needs, including elderly eye disease diagnosis and treatment, in response to an aging population [2] - Transitioning from "single service" to "lifecycle service" to provide comprehensive eye health management [2] Group 3: International Business Growth - International operations are seen as a key growth area, with strategies focusing on careful expansion and local operations [3] - In Europe, a combination of acquisitions and new establishments has led to significant growth, with further potential for expansion [3] - The company retains local brands and management teams in overseas markets to ensure smooth integration and cultural alignment [4] Group 4: Technological Advancements - Continuous investment in eye care technology is crucial, with advancements in diagnostic and treatment methods driving industry progress [5] - The company covers a wide range of services, including refractive surgery and cataract treatment, forming a comprehensive eye care system [5] - Focus on integrating AI and digital health solutions to enhance service delivery and clinical research [5] Group 5: Response to Policy Changes and Competition - The company recognizes the impact of aging populations on healthcare funding and aims to expand its patient base through improved management and service quality [6] - Emphasis on developing non-insured services to create a differentiated competitive advantage [6] - The domestic market remains competitive, with the company leveraging its technological and service strengths to increase market share [6] Group 6: Talent Development and Incentives - A multi-layered incentive system is established to motivate staff and align their interests with the institution's performance [7] - Collaboration with educational institutions to cultivate high-level professionals and enhance existing team capabilities [7] - Focus on integrating clinical practice, education, and research to foster talent growth [7] Group 7: Strategies Against Industry Challenges - The company advocates for healthy competition in the medical field, emphasizing patient safety over cost-cutting [9] - Cost reduction strategies include process optimization and digital tools, while maintaining service quality [9] - Continuous technological innovation is essential to avoid price wars and enhance patient satisfaction [9]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant allocation in leading healthcare companies [1][3]. - As of July 15, 2025, the latest net value of the fund is 1.7462 yuan, reflecting a growth of 1.28%. The fund's one-month return is 2.18%, six-month return is 18.43%, and year-to-date return is 14.30% [1]. - The fund's top ten stock holdings account for a total of 55.30%, with significant investments in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1]. Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan. The fund is managed by Guo Lan and Zhao Lei [1]. - Guo Lan, the fund manager, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]. - Zhao Lei, also a fund manager, has experience in the pharmaceutical and biotechnology sectors, having worked as a researcher and analyst before joining China Europe Fund Management in 2021 [2].

Group 1 - The article highlights the rising costs and pressures faced by parents regarding their children's health, particularly in managing myopia, dental issues, and height concerns [2][57] - A significant market has emerged around myopia treatment, with the overall myopia rate among children and adolescents in China reaching 52.7%, indicating that one in two children is affected [27][28] - Companies in the myopia treatment sector, such as Opcon Vision and Aier Eye Hospital, are experiencing substantial revenue growth, with Opcon Vision's revenue reaching 1.814 billion and Aier Eye Hospital's revenue at 20.983 billion [30][31] Group 2 - The orthodontics market is also booming, with companies like Times Angel and Invisalign dominating the space, capturing significant market shares and generating substantial revenues [43][44] - The article discusses the high costs associated with dental treatments, with some families spending up to 60,000 on orthodontic solutions, reflecting a growing trend in dental care for children [34][36] - The prevalence of dental issues among children is alarming, with a reported 67.82% incidence of malocclusion, leading to increased demand for orthodontic services [41] Group 3 - Height management is emerging as a new area of concern for parents, with the market for growth hormone treatments and related products projected to reach 8-12 billion, growing at a compound annual growth rate of over 25% [56][57] - Companies like Jinsai Pharmaceutical are leading the growth in the height management sector, with a reported revenue of 10.67 billion, indicating a strong market presence [56] - The societal pressures regarding height are reflected in the increasing willingness of parents to invest heavily in treatments, with some spending tens of thousands on growth hormone therapies [48][49]

Group 1 - The medical health ETF Taikang (159760) has seen a 0.17% increase, marking its fifth consecutive rise, while the index it tracks, the National Certificate Public Health and Medical Health Index (980016), rose by 0.13% [1] - As of July 14, the latest scale of the medical health ETF Taikang reached 82.4979 million yuan, a new high in nearly three months [2] - The medical device sector is expected to experience a performance turning point, driven by policies such as the old-for-new program and the gradual clearance of channel inventory [2] Group 2 - The top ten weighted stocks in the National Certificate Public Health and Medical Health Index account for 51.67% of the index, with leading companies including WuXi AppTec (603259) and Hengrui Medicine (600276) [3] - The CDMO sector has rebounded, with WuXi AppTec expected to see significant growth in revenue and profit by mid-2025, indicating strong global market demand [2] - The innovation drug industry chain is anticipated to enter a new upward cycle, supported by an improving domestic investment environment and active financing activities [2]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a slight increase of 0.39% recently, reflecting the overall performance of listed companies in the healthcare sector [1] Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services is currently at 13,682.83 points with a trading volume of 18.089 billion [1] - Over the past month, the index has decreased by 0.83%, while it has increased by 2.95% over the last three months, and has seen a year-to-date decline of 0.43% [1] Group 2: Index Composition - The index is composed of listed companies that correspond to the healthcare theme, with a base date of December 31, 2004, set at 1,000.0 points [1] - The top ten weighted companies in the index include: Mindray Medical (9.44%), United Imaging (8.04%), Aier Eye Hospital (7.55%), Aimeike (3.41%), Huatai Medical (3.23%), New Industry (2.81%), Yuyue Medical (2.7%), Lepu Medical (2.54%), Meinian Onehealth (2.05%), and Shandong Pharmaceutical Glass (1.91%) [1] Group 3: Market Distribution - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.09%) and the Shanghai Stock Exchange (39.91%) [1] - The healthcare sector accounts for 100% of the index's holdings [1] Group 4: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Public funds tracking the healthcare index include various Southern and Tianhong funds, as well as ETFs from multiple financial institutions [2]

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-048 爱尔眼科医院集团股份有限公司 关于使用部分闲置自有资金进行现金管理的实施公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日召开第六届董事会第三十二次会议和第六届监事会第二十次会议，审议通过了 《关于使用部分闲置自有资金进行现金管理的议案》，同意公司在保证日常经营 资金需求和资金安全的前提下，使用不超过人民币 15 亿元的闲置自有资金购买 安全性高、流动性好、风险性低的理财产品，期限为自公司第六届董事会第三十 二次会议决议之日起 12 个月。在上述额度及期限内，资金可循环滚动使用，由 公司财务中心负责具体购买事宜。上述内容详见公司 2025 年 3 月 24 日在巨潮资 讯网（www.cninfo.com.cn）披露的相关公告。 根据上述决议，公司于近期办理了投资理财业务。现就具体事项公告如下： 一、本次使用部分暂时闲置自有资金进行现金管理的实施情况 产品名称：浦银理财周周鑫最短持有期 55 号理财产品 理财币种 ...

Core Viewpoint - The article emphasizes the importance of long-term value investing and the need for investors to remain patient and focused on their investment goals, even when market trends do not align with their current holdings [2][3]. Group 1: Market Trends and Investment Strategy - The current market is characterized by a focus on bank stocks and small-cap stocks, which the author's friend's portfolio lacks, leading to underperformance compared to market trends [2]. - A portfolio consisting of high ROE stocks can outperform the market over the long term, provided that investors are not overly focused on short-term gains [3]. - Investors should be cautious of high-risk investments, as most individuals lack the ability to manage such risks effectively, and high returns are not guaranteed [4]. Group 2: Valuation Metrics - The banking sector currently has a dividend yield of around 4%, but the high leverage involved poses significant risks, making it less attractive compared to lower-leverage consumer stocks with similar yields [4]. - The current PE ratio of the CSI 2000 index is 132, placing it in the 92.36th percentile historically, indicating limited upward potential [4]. - The PB ratio of the CSI 2000 index is 2.46, which is in the 94.98th percentile historically, suggesting that valuations are stretched and may not support further price increases [4][5]. Group 3: Investment Philosophy - The article advocates for a rational and detached approach to investing, where investors avoid chasing trends and instead focus on the long-term value of their holdings [5]. - The "Snowball Three-Point Method" is introduced as a strategy for long-term investment and asset allocation, emphasizing diversification across assets, markets, and timing to achieve risk mitigation and diversified returns [6].

金融界2025年7月9日消息，中欧医疗健康混合C(003096) 最新净值1.6608元，增长0.94%。该基金近1个 月收益率-0.94%，同类排名1094|1252；近3个月收益率16.34%，同类排名306|1238；今年来收益率 10.10%，同类排名434|1218。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券 ...